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Abstract
Background: Type 2 diabetes is a prevalent chronic condition globally that results in extensive morbidity,
decreased quality of life, and increased health services utilization. Lifestyle changes can prevent the development
of diabetes, but require patient engagement. Genetic risk testing might represent a new tool to increase patients’
motivation for lifestyle changes. Here we describe the rationale, development, and design of a randomized
controlled trial (RCT) assessing the clinical and personal utility of incorporating type 2 diabetes genetic risk testing
into comprehensive diabetes risk assessments performed in a primary care setting.
Methods/Design: Patients are recruited in the laboratory waiting areas of two primary care clinics and enrolled
into one of three study arms. Those interested in genetic risk testing are randomized to receive either a standard
risk assessment (SRA) for type 2 diabetes incorporating conventional risk factors plus upfront disclosure of the
results of genetic risk testing ("SRA+G” arm), or the SRA alone ("SRA” arm). Participants not interested in genetic risk
testing will not receive the test, but will receive SRA (forming a third, “no-test” arm). Risk counseling is provided by
clinic staff (not study staff external to the clinic). Fasting plasma glucose, insulin levels, body mass index (BMI), and
waist circumference are measured at baseline and 12 months, as are patients’ self-reported behavioral and
emotional responses to diabetes risk information. Primary outcomes are changes in insulin resistance and BMI after
12 months; secondary outcomes include changes in diet patterns, physical activity, waist circumference, and
perceived risk of developing diabetes.
Discussion: The utility, feasibility, and efficacy of providing patients with genetic risk information for common
chronic diseases in primary care remain unknown. The study described here will help to establish whether
providing type 2 diabetes genetic risk information in a primary care setting can help improve patients’ clinical
outcomes, risk perceptions, and/or their engagement in healthy behavior change. In addition, study design features
such as the use of existing clinic personnel for risk counseling could inform the future development and
implementation of care models for the use of individual genetic risk information in primary care.
Trial Registration: ClinicalTrials.gov: NCT00849563
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The judicious use of genetic and genomic information
has significant, if untested, potential to enhance the clin-
ical care and prevention of chronic diseases - both indir-
ectly, by contributing to our understanding of disease
biology, as well as more directly, by providing additional
information to influence providers’ screening and treat-
ment recommendations and patients’ engagement and
health behaviors [1].
T y p e2d i a b e t e sr e p r e s e n t sah i g h l yr e l e v a n ta n d
important example of a genetically complex chronic dis-
ease. Over 20 million people currently suffer from dia-
betes in the US alone, and more than a million new
cases are diagnosed each year [2]. High blood glucose is
a leading cause of death around the world [3]. There is
strong evidence that lifestyle changes can delay progres-
sion to diabetes, even in high-risk individuals, for at
least a decade [4]. However, uptake of recommended
behaviors appears disappointingly low, as evidenced by
skyrocketing rates of obesity in the US and globally, dri-
ven by multiple factors [5-7]. Recent reviews of diabetes
prevention and screening have thus articulated the need
for more effective strategies for increasing patients’
motivation and improving adherence to lifestyle changes
which have been shown to reduce risk for type 2 dia-
betes [8,9].
To date, approximately 40 common DNA variants, or
single nucleotide polymorphisms (SNPs), have been
found to be associated with increased risk for type 2
diabetes [10,11]. One limitation to the broader applica-
tion of such testing is that the magnitude of increased
risk conferred by each variant is relatively small
(although there is evidence that testing for these 40 var-
iants can improve reclassification of diabetes risk for
individuals under the age of 50 [11]). Thus, genetic risk
testing for these variants may not yet offer significant
predictive value for individual patients sufficient to alter
providers’ screening and treatment recommendations.
Genetic risk information, however, could have clinical
utility in other ways.
Clinical utility (defined as net benefit in improving
health outcomes) of genetic testing could be demon-
strated through increasing patient activation or posi-
tively influencing patient attitudes, beliefs, and health-
related behaviors [12]. The relatively scarce research
into clinical utility of genetic testing has produced
mixed results [13,14]; however, some studies have found
evidence that providing results of genetic tests for
chronic diseases increases patients’ preventive behavior
[15,16]. A recent systematic review of the impact of
genetic risk information on chronic adult diseases found
some psychological benefits of including genetic infor-
mation in treatment of chronic diseases, but concluded
that many gaps in knowledge must be addressed before
genetic science can be effectively translated into clinical
practice [13].
In this paper, we describe the development, design,
and methods of a randomized controlled trial (RCT)
designed to assess the clinical utility of incorporating
type 2 diabetes genetic risk testing into comprehensive
diabetes risk assessments performed in primary care.
The intervention tested in this RCT is integrated into a
primary care setting and includes a theory-based tool to
communicate risk of developing type 2 diabetes to
patients. This study does not focus on the predictive uti-
lity of the genetic test per se; rather, it focuses on
whether adding genetic test results to standard risk
assessment affects patients’ clinical outcomes, behaviors,
and perceptions.
Conceptual framework: Altering patient risk perceptions
A potential role for genetic risk information in disease
prevention efforts is described by the Common Sense
Model (CSM) of self-regulation of health and illness,
adapted by Marteau and Weinman [17] to explain
patient responses to health risk information. Health risk
information (internal or environmental) informs the
cognitive representation of and/or the emotions asso-
ciated with a health threat, which in turn activates a
coping plan, followed by an appraisal of the coping plan
[18]. The appraisal then feeds back to update both the
representation and coping plan in a continuous,
dynamic fashion.
Genetic risk information could provide a distinct
type of information to the cognitive representation of
type 2 diabetes risk. For instance, the construction of
beliefs about personal health risks may be derived in
part from an individual’s experience of the pattern of
d i s e a s ee x p r e s s i o ni nt h e i rfamilies [19]. However,
patients may discount family history information
because they feel different in crucial ways from
affected relatives [20]. Genetic risk information that is
specific to the individual cannot be discounted in the
same way, and thus may carry added personal signifi-
cance for patients. Genetic information might engen-
der heightened perceived risk (i.e., anticipated harm if
no action is taken), increased emotional response, and
then formulation of a coping plan. Accordingly, our
hypothesized mechanism of the effect of genetic risk
information is that it increases perceived risk, which
will in turn increase motivation to engage in coping by
increasing preventive health behaviors. Genetic risk
information may also serve as a more durable remin-
der of threat over time, and serve to reinforce the
importance of the coping plan through the appraisal
process [21].
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This study is funded with support from The Duke
Endowment (Charlotte, NC), approved by the Duke
University Health System Institutional Review Board,
and registered at ClinicalTrials.gov (NCT00849563).
Overview
This RCT consists of three study arms (see Figure 1).
Study coordinators tell prospective participants about
the availability of genetic testing for diabetes risk, and
ask them if they would be interested in undergoing such
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NO
Decline testing
SRA+G
Standard Risk Assessment
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SRA
Standard Risk Assessment
Only
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Figure 1 Study flow.
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informed consent to participate and having eligibility
confirmed, those interested in genetic testing are ran-
domly assigned to undergo either a standard risk assess-
ment (SRA) for type 2 diabetes plus upfront disclosure
of the results of genetic risk testing (SRA+G), or the
SRA alone (SRA). (The standard SRA incorporates the
conventional risk factors of fasting glucose, body mass
index (BMI), race/ethnicity, and age.) Patients not inter-
ested in genetic testing for diabetes risk are not rando-
mized and receive only the SRA in a third study arm
(No-Test).
Participants are also asked to complete four study
encounters over 13 months: In-person visits at baseline
and for risk counseling (approximately 4-6 weeks after
baseline), a remote 3-month survey (i.e., 3 months after
risk counseling), and a 12-month end-of-study visit.
Height and weight (to calculate BMI), waist circumfer-
ence, fasting plasma glucose and fasting insulin levels
are measured at baseline and 12 months. Buccal swabs
for DNA collection are obtained from all participants
interested in genetic risk testing at the baseline visit.
Surveys completed at each encounter will be used to
track patients’ behavioral and emotional responses to
diabetes risk information over time, including percep-
tions of personal risk for type 2 diabetes. Primary out-
comes are changes in insulin resistance and weight;
secondary outcomes are changes in diet, physical activ-
ity, and waist circumference.
Settings, eligibility, and recruitment
Patients are recruited in the clinical laboratory waiting
areas of two primary care outpatient clinics - one an
internal medicine practice, the other a family medicine
practice -located in Durham County, North Carolina
(NC), in the southeastern United States. These clinics
serve a cross-section of Durham residents in terms of
age, sex, race, and payor mix, and are affiliated with an
academic health system. Durham County itself has a
high prevalence of chronic disease and risk factors for
disease. In 2007, 9% of all Durham County residents
(14% of African-American residents) reported having a
diagnosis of diabetes, 30% of residents were obese, and
an additional 34% were overweight [22].
Study inclusion criteria are as follows: between the
ages of 18 and 81 years; no self-reported history of dia-
betes; no self-reported history of prior genetic testing
for diabetes risk; and not currently pregnant. To reduce
the burden of participation, participants in the clinic
who are already awaiting a fasting glucose draw or panel
of tests that included glucose are invited to participate.
Prospective participants are excluded if: they are taking
or had taken medications normally used to treat dia-
betes; if baseline fasting glucose (tested at enrollment) ≥
7m m o l / L( ≥ 126 mg/dL), indicating possible undiag-
nosed diabetes; if they are not fasting and are unwilling
to return for a fasting blood test; if baseline surveys are
not completed; or if they cannot provide informed con-
sent unassisted.
Participants will receive $20 for each of the three in-
p e r s o ns t u d yv i s i t sa n da r ee l i g i b l ef o rd r a w i n g sf o r
additional cash prizes for completing the 3-month survey
and 12-month visit.I na d d i t i o n ,t h o s ei n t e r e s t e di n
genetic testing who are randomized to the SRA arm are
given the option of receiving their diabetes genetic risk
results after completing the 12-month visit and conclud-
ing their participation in the study.
Randomization
Randomization assignments are made when buccal swab
samples are received from the two clinic sites at a cen-
tral location, by study staff not installed at the clinical
sites, and prior to sending the samples off for testing.
This arrangement, in addition to obtaining buccal swabs
from all participants interested in genetic risk testing,
has the effect of blinding both participants and study
staff at each clinic site to which arm participants have
been randomized, until participants return for risk
counseling.
Genetic risk testing
Among the best-studied - and most predictive - SNPs
associated with increased risk for developing type 2 dia-
betes, are two closely linked SNPs (rs7903146 and
rs12255372) in the TCF7L2 gene; in both, the T allele is
the higher-risk variant. More than 30 studies have repli-
cated the finding that these two SNPs in TCF7L2 are
associated with increased type 2 diabetes risk in White,
Asian, and African American populations [23]. Partici-
pants in the Diabetes Prevention Program (DPP) study
who were TT homozygous (i.e., had two higher-risk var-
iants) at either of the two SNPs in the TCF7L2 gene
had an increased risk of progression from impaired glu-
cose tolerance to type 2 diabetes compared with partici-
pants who were CC and GG homozygous (with hazard
ratios = 1.55 and 1.53, respectively) [24].
In the current study, one of these SNPs in the
TCF7L2 gene, along with SNPs from three other genes
(CDKN2A/2B, CDKAL1, and PPARG), reproducibly
found to be associated with increased risk for type 2
diabetes, will be genotyped [10]. DNA is obtained via
buccal swab from all participants who consent to
genetic risk testing and is sent to a Clinical Laboratory
Improvement Amendments (CLIA)-certified laboratory
for testing (deCODE genetics, Chicago, IL). The con-
scious decision to use a commercially-available test from
a CLIA-certified laboratory - rather than performing
testing in a research laboratory - was made in order to
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significant study findings.
Family history
Self-reported family history of type 2 diabetes is assessed
by asking respondents to report the number of first-
degree (mother, father, brothers and sisters, children)
and second-degree (maternal and paternal aunts, uncles,
and grandparents) biological relatives with type 2 dia-
betes. Following the algorithm described in Hariri et al.
[25], participants are classified into average, moderate or
high familial risk for type 2 diabetes.
Risk profiling
Diabetes risk profile
At the time of their risk counseling visits, all partici-
pants receive a pictorial profile indicating their status
with respect to individual risk factors for type 2 diabetes
(see Figure 2). The profile used in this study was devel-
oped by a multi-disciplinary working committee, which
included clinicians, genetic counselors, and a risk com-
munication expert.
Age is included as a separate risk factor only for parti-
cipants over 45 years of age. Race/ethnicity is included
only when participants report Hispanic ethnicity, or
African-American and/or Native American race, these
being groups at elevated risk for type 2 diabetes.
In addition, each risk factor-containing box is color-
coded to suggest different degrees of risk and aid in the
communication of relative risks to the patient. For
example, for the fasting glucose results, the background
color would be red if the glucose test result is between
100 and 125 mg/dL, with the notation, “This means that
you are ‘prediabetic,’ which puts you at High Risk for
diabetes. You should probably see your doctor to follow
up this test result. 1 out of 4 people with a blood sugar
this high gets diabetes in the next 3 to 5 years.” Conver-
sely, the background color for this section would be yel-
low if the glucose test result is less than 100, with the
notation, “This result falls in the normal range. What
this means for your risk for diabetes depends on other
risk factors, such as those below.” BMI 30 and above (i.
e., obese) would be colored red, between 25 and 30 (i.e.,
overweight) orange, and BMI less than 25 (i.e., normal)
yellow. Age greater than 45 years of age and higher-risk
race/ethnicity are color-coded orange.
Genetic risk appears on the profile only for partici-
pants randomized to receive upfront disclosure of
Figure 2 Risk profile (used to communicate patient risk for developing type 2 diabetes).
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is presented as the number of higher-risk alleles for
each of the four SNPs included in the diabetes genetic
risk test used in this study (i.e., “You have Xo u to f8
possible higher-risk DNA changes tested for in four
genes linked to higher diabetes risk”). Participants
homozygous for the higher-risk TCF7L2 (T) allele are
given the additional information that overweight indivi-
duals with this genotype and prediabetes have approxi-
mately double the risk for progression to type 2 diabetes
[24,26].
Participants receiving genetic risk results (SRA+G) are
also given the official deCODE test report, which pre-
sents a combined genetic risk for type 2 diabetes as an
odds ratio with an explanation of these results. Partici-
pants’ primary healthcare providers are not given copies
of either the risk profile or the deCODE test report, and
participants are neither encouraged nor discouraged
from sharing this information on their own.
Web-based risk profile generator
Through iterative meetings led by a faculty informati-
cian, specifications were developed to operationalize the
profile as a web-based tool. A Web portal was then
developed which collects these risk factors in a de-iden-
tified manner and generates a PDF risk profile based on
these risk factors. The underlying technologies used in
this Web portal were Java Server Pages for the Web
development, Java for the software engineering, XML
for the patient data representation, and XSL-FO in con-
junction with the Apache Formatting Objects Processor
for the conversion of the XML data into human-read-
able PDF risk profiles. The XSL-FO stylesheet was gen-
erated using commercial software (Altova StyleVision
Enterprise Edition).
Risk counseling
Training of embedded clinic staff
Embedded healthcare providers already involved in the
clinical care of patients at each site - a clinical pharma-
cist (who is also a certified diabetes educator, or CDE)
and a physician assistant at the family medicine clinic;
and a nurse practitioner at the internal medicine clinic -
h a v eu n d e r g o n ea2 - h o u rt r a i n i n gt oe n s u r et h a tr i s k
information is consistently and accurately presented in
easy-to-understand language and manner, with standar-
dized content. The training session was developed and
led by a certified genetic counselor, in consultation with
a faculty researcher in risk communication, both of
whom have extensive experience in genetic risk commu-
nication. Didactic, discussion, and role-playing activities
focused on developing a knowledge base and strategies
for communicating genetic and non-genetic risk
information, as well as counseling regarding desirable
lifestyle change [27,28].
Delivery of risk assessment results
Risk counseling appointments will be scheduled for each
participant with one of the trained embedded healthcare
provider(s) at that participant’s regular clinic. These
appointments will occur approximately 3-6 weeks after
the baseline visit, sample collection, and return of
genetic testing results (if any). To facilitate uniformity of
counseling content, the risk profile described above will
be used to guide the order of the visit.
Additional resources
Participants are provided with several additional
resources to aid in the comprehension of diabetes risk
information and implementation of diabetes prevention
behaviors, including educational materials on diet, exer-
cise, weight loss, and strategies for lowering risk for type
2 diabetes; a list of online resources compiled from stan-
dard diabetes education materials to facilitate active
learning about type 2 diabetes, diabetes risk, and dia-
betes prevention; and the NHGRI publication AG u i d e
to Your Genome, a 12-page booklet with information
about genome science, genetic tests, and genome
research. Participants are also provided with access to
an online health portal, The PHD Network (Personal
Health Development Network; http://www.activhealth.
com). This health portal includes tools for assessing per-
sonal health risks for conditions including type 2 dia-
betes, as well as educational materials, health
assessments, and behavioral goal-setting and tracking
tools.
Study measures: Outcomes
Primary clinical outcomes are changes in insulin resis-
tance and weight over 12 months. Change in insulin
resistance will be assessed by measuring fasting insulin
and serum glucose levels at baseline and 12 months,
and calculating the homeostasis model assessment of
insulin resistance (HOMA-IR). The HOMA-IR is a
widely-used measure of insulin resistance that is tightly
correlated with the criterion standard of direct measure-
ment by insulin clamp technique [29,30]. Change in
weight will only be analyzed among overweight and
obese patients (because healthy-weight patients will pre-
sumably not be counseled to lose weight). Weight at 12
months will control for baseline weight; specifically, the
12-month weight outcome variable will be residualized
change scores (residuals captured from regressing 12-
month weight onto baseline weight).
Secondary clinical outcome measures will be changes
in diet, energy expenditure, and waist circumference.
Change in diet will be measured using the 16-item diet-
ary subscale from the National Health Interview Survey
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using the World Health Organization’s (WHO) Global
Physical Activity Questionnaire [32]. Waist circumfer-
ence will be measured at baseline and 12 months; the
waist is defined as the midpoint between the highest
point of the iliac crest and the lowest point of the costal
margin at the midaxillary line [33]. All 3-month and 12-
month outcome variables will be residualized change
scores.
Process Measures
Surveys will assess several process variables at several
time points. Belief in the role of genetics in type 2 dia-
betes risk and perceived personal risk for type 2 diabetes
are measured with newly designed items based on Com-
mon Sense principles. Affective response to diabetes risk
are measured with the Consequences subscale of the
Brief Illness Perception Questionnaire [34] and the Mul-
tidimensional Impact of Cancer Risk Assessment
(MICRA) Questionnaire [35], both adapted to type 2
diabetes. Perceived control over risk for type 2 diabetes is
measured with the personal control subscale of the Brief
IPQ (adapted for type 2 diabetes).
Analyses
Data will be analyzed according to intention-to-treat
principles. Data will be checked for completeness and
the characteristics and frequency of missing data will be
described. Missing data values will be imputed as
appropriate.
Our primary hypothesis is that patients in the SRA+G
arm will have a greater reduction in insulin resistance
and lose a greater percentage of their baseline weight
after 12 months compared to patients in the SRA arm.
We will test these hypotheses with linear multiple regres-
sion models with weight or insulin resistance at 12
months as the outcomes (testing a separate model for
each outcome) and arm, clinic site, and baseline patient
characteristics as explanatory and control variables. We
will test our hypothesized mechanism with mediation
analysis; specifically, hierarchical linear regression models
will test whether effects of the intervention on insulin
resistance and weight at 12 months is partially or fully
accounted for by perceived risk at 3 months.
Our secondary hypotheses are that patients in the
SRA+G group will report significantly healthier dietary
changes and will have significantly greater average
weekly energy expenditure than patients in the SRA
group after 3 months. We will test this hypothesis with
linear multiple regression models with behavioral vari-
ables at 3 months as the outcomes (testing a separate
model for each variable) and arm, clinic site, and base-
line patient characteristics as explanatory and control
v a r i a b l e s .W ep r e d i c tt h a tt h i sd i f f e r e n c ew i l ln a r r o w ,
but will still be significant at 12 months; we will test
this hypothesis by fitting the same regression model
with 12-month behavioral variables as outcomes. In
addition, we hypothesize that overweight and obese
patients in the SRA+G group, irrespective of diabetes
genetic panel test result, will have a greater reduction in
waist circumference. Residualized change scores (con-
trolling for baseline values) will be used for 3- and 12-
month outcome variables.
We will analyze the roles of process variables using
moderation analyses in linear regression models. We
predict (1) that patients who believe genetics plays a
greater role in their risk of type 2 diabetes will be more
likely to improve diet and exercise behavior at 3 months
than those who believe genetics plays a lesser role in
their diabetes risk; (2) that patients with higher per-
ceived personal risk for Type 2 diabetes - regardless of
actual test results, and regardless of group assignment -
will be more likely to improve diet and exercise behavior
at 3 months; (3) that patients with more positive affec-
tive responses (e.g., not anxious, guilty, or fearful) and
more concern about their risk for type 2 diabetes -
regardless of actual test results, and regardless of group
assignment - will be more likely to improve diet and
exercise behavior at 3 months; and (4) that patients with
higher perceived control over their risk for type 2 dia-
betes will be more likely to maintain dietary and exer-
cise behavior changes at 12 months.
Power and sample size considerations
Power and sample size estimates are based on the pri-
mary study outcomes, percent weight change (from
baseline) and change in HOMA-IR, both after 12
months. Based on two studies of low-intensity clinic-
based weight loss interventions, we estimate that
approximately 20% of patients in the SRA+G arm will
lose 5% of their body weight over the course of a year,
compared to approximately 10% of patients in the SRA
arm [36,37]. Under these assumptions, the mean weight
change for participants in the SRA+G arm is estimated
to be around 1.7% of baseline body weight, with a stan-
dard deviation of approximately 3.9; and the mean
weight change to be zero in the SRA arm. We further
assume that changes in weight follow normal distribu-
tions with equal standard deviations for both groups.
Because we are studying a low-intensity informational
intervention, for purposes of sample size calculation we
will aim for sufficient power to detect a difference in
weight change that is 2/3 of the 1.7% difference esti-
mated above. Thus, approximately 198 patients are
needed in each group for a two-sided type I error rate
of 0.05 and 80% power.
From a number of comparable studies, we conserva-
tively estimate that participants in the SRA+G arm will
Cho et al. BMC Health Services Research 2012, 12:16
http://www.biomedcentral.com/1472-6963/12/16
Page 7 of 11be able to lower HOMA-IR by 0.5 over the course of a
year through lifestyle changes; those in the SRA arm are
again assumed to have a mean change of zero. Mean
baseline HOMA-IR is estimated to be 2.5 with a stan-
dard deviation near 2.0 [38-41]. Using these estimates,
253 patients per group would be required to achieve a
significance level of 0.05 with 80% power.
Discussion
An important gap suggested by AHRQ-EPC [42] and
USPSTF [43] reviews is the relative lack of effective stra-
tegies for increasing patients’ motivation for and adher-
ence to lifestyle changes known to reduce risk for type 2
diabetes. The study described herein examines a novel
alternative strategy, in which patients are counseled
about their germline genetic risk for type 2 diabetes as
part of a comprehensive risk assessment. To our knowl-
edge this is the first RCT to assess the clinical utility of
disclosing the results of DNA testing for common var-
iants associated with increased risk for type 2 diabetes.
Study outcomes include patients’ emotional and beha-
vioral responses to this additional information, behavior
changes (if any), and clinical endpoints. In addition, this
study also addresses the personal utility of DNA testing.
O u rh y p o t h e s i z e dm e c h a n i s mo fe f f e c ti st h a tp r o v i s i o n
of type 2 diabetes genetic risk information during the
risk counseling intervention will alter perceived risk,
which will in turn increase motivation to engage in pre-
ventative health behaviors. Personal utility captures
potential benefits of DNA testing that cannot necessarily
be directly quantified in clinical outcomes [44].
Because this is one of the first trials to test for beha-
vioral and clinical effects of communicating genetic test
results, we carefully considered several novel and impor-
tant issues during its development and design.
Ethics of Communicating Genetic Risk Information
Adding genetic testing to standard risk assessment
provides little improvement in the degree of absolute
prediction of risk for developing type 2 diabetes. In
designing the risk profile, we aimed to facilitate fram-
ing and evaluation of individual risk through sugges-
tions of magnitude and meaning of results, and also to
avoid falsely reassuring or overly alarming messages.
By abstaining from presenting normative statements
regarding the degree of genetic risk, we sought to keep
participants from developing notions of fatalism or
false security that might undermine motivation to
change behavior [39].
Strategy for Risk Communication
We aimed to simplify the presentation of risk informa-
tion to be complete yet readily understood by patients.
To this end, our risk profile (1) placed genetic risk
information in context alongside other major risk factors
for type 2 diabetes, (2) did not require a sophisticated
understanding of either genetics or statistics, and (3)
communicated personalized, evidence-based messages
regarding individual risk which could then be further
explained and amplified during the risk counseling visit
(see Figure 2). This profile can readily be expanded to
incorporate additional genetic risk markers for type 2
diabetes; and could even be adapted for use in other
chronic diseases (e.g., coronary heart disease).
Combining different categories of risk information
represented a particular challenge, especially given that
patients’ understanding and evaluation of their various
risks are highly individualized. While the magnitude of
risk may be a computable, objective quantity, the mean-
ing of that risk for the individual is subjective and quali-
tative, and affected by many factors [45]. Genetic
epidemiology has thus far almost exclusively focused on
quantitative precision, and as a result, probably overem-
phasizes the significance of exactness when informing
individual patients of their risks for a chronic disease.
With this in mind, our risk profile was based on pro-
spect theory, an established framework for understand-
ing risk assessment and decision-making that has been
previously applied to framing risk messages to promote
healthy behavior [46,47]. Prospect theory posits two
phases: editing (or framing) and evaluation; our risk pro-
file was designed to address both.
The editing (or framing) stage is where the decision-
maker’s reference point is determined. We chose not to
frame patients’ risk information as a single quantity (i.e.,
“You have x% risk of getting diabetes in the next y
years”) for two reasons: First, there does not yet exist a
comprehensive (prospective) risk prediction tool that
combines and quantifies all of the known risk factors
for type 2 diabetes, even excluding genomic risk. Sec-
ond, individual differences in numeracy would likely
have resulted in variation in understanding such a quan-
tity [48]. Instead, we chose to simultaneously present
patients with a number of distinct factors contributing
to their overall risk for type 2 diabetes in relatively sim-
ple terms. Patients can evaluate each contributing risk
factor in its own right, and each individual can arrive at
an overall gestalt rather than having to interpret an
abstract quantity.
Patients’ valuing and weighting the overall risk for
type 2 diabetes as a product of accepted, understood
risk factors is described by prospect theory’s evaluation
phase. In our risk profile, different suggestive colors are
used to highlight different degrees of risk for each fac-
tor. Simple quantitative reports and explanations are
used to report blood sugar, number of relatives with
type 2 diabetes, number of higher-risk alleles, and other
risk factors (this “semi-quantitative” approach is based
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tive to other individuals or other risks [49]).
Strengths of the Study
First, to increase the potential generalizability of the
study to other primary care settings, we made the delib-
erate decision to use embedded clinicians already practi-
cing at each clinic site to provide risk counseling, rather
than inserting study personnel or referring study partici-
pants to outside genetic counselors. Second, to increase
the potential for replication of any findings, we chose
not to implement a supplementary behavioral interven-
tion along with risk counseling. Although such a beha-
vioral intervention might increase the effectiveness of
risk counseling for increasing preventive behaviors, it
also might have the effect of complicating the identifica-
tion of unique effects of genetic testing. In addition, in
many primary care settings, a discrete behavioral inter-
vention may not be feasible due to cost and other
resource constraints. Third, our risk counseling protocol
is theory-based and relatively simple, maximizing the
possibility that should the intervention prove successful,
it might be more readily replicated in other settings
with few additional resources required. In summary,
although the main outcome measures are designed to
test the effects of genetic risk information on clinical
and behavioral outcomes related to prevention of a par-
ticular chronic disease (i.e., type 2 diabetes), results
from this study could also inform the future develop-
ment and implementation of care models for the use of
individual genetic risk information in primary care more
generally.
Conclusion
The clinical and personal utility, feasibility, and efficacy
of providing patients with genetic risk information for
common chronic diseases in primary care remain largely
unknown. The novel study described here aims to
address these knowledge gaps, and the findings will con-
tribute to the evidence base regarding the use of genetic
risk testing to promote behaviors that reduce the risk of
type 2 diabetes and other diseases. In addition, study
design features such as employing existing clinic person-
nel for risk counseling and the creation of a comprehen-
sive risk communication tool that includes both genetic
and non-genetic factors, could be adapted for other set-
tings and chronic conditions of interest, informing the
future development and implementation of care models
for the use of individual genetic risk information in pri-
mary care.
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